KRAS G12C
Clinical trials for KRAS G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C trials appear
Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a custom-made vaccine using a patient's own immune cells, designed to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given together with two immunotherapy drugs to boost the immune system's attack on tumors. The study includ…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated May 17, 2026 04:25 UTC
-
New immunotherapy targets tough cancers with gene mutations
Disease control OngoingThis study tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to help the immune system recognize and attack cancer cells after standard therapies like surgery an…
Matched conditions: KRAS G12C
Phase: PHASE1, PHASE2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New hope for hard-to-treat cancers: experimental drug enters human testing
Disease control OngoingThis early-stage study tests a new drug called TT125-802 in about 50 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also watch for signs that the drug sh…
Matched conditions: KRAS G12C
Phase: PHASE1 • Sponsor: TOLREMO therapeutics AG • Aim: Disease control
Last updated May 06, 2026 16:02 UTC